Project Grant R41AA031392
Award Date
9/25/23
Completion Date
8/31/24
Dollars Obligated
$369K
Federal Agency
National Institute on Alcohol Abuse and Alcoholism
Awardee
Artiam Bio Inc. (FKJAXBQEDUJ8)
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $999,393 Cooperative Agreement under the Alcohol Research Programs (CFDA 93.273) to Stress Therapeutics, Inc. on May 15, 2025. The purpose of this Phase I SBIR grant is to initiate investigational new drug (IND)-enabling studies for an innovative first-in-class therapeutic candidate aimed at chronic management of pathological hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis for the treatment of alcohol use...
This $545,282 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, aims to study the neural mechanisms associated with cognitive reappraisal and alcohol cue reactivity in individuals with alcohol use disorder (AUD) during early abstinence. The primary objectives are to: 1) determine how neural mechanisms related to reappraisal and alcohol cue-reactivity change across early abstinence...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $581,869 Project Grant under the Alcohol Research Programs (CFDA 93.273) to The University of Kentucky Research Foundation. The purpose of this 4-year project, commencing on Aug 1, 2024, is to conduct a rigorous crossover study translating preclinical findings on glucocorticoid receptor (GR) antagonism to humans with alcohol use disorder (AUD). Using the selective GR antagonist PT150, the study will assess its effects on...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $498,121.57 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of New Mexico on August 15, 2024. The grant will fund research to investigate the neural mechanisms underlying maladaptive coping behaviors to stress and subsequent alcohol use disorders, with a focus on sex differences. Specifically, the project will utilize chemogenetic, electrophysiological, and optogenetic techniques to examine...
This $499,442 Project Grant was awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program. The grant supports research on the role of brain-derived neurotrophic factor (BDNF) signaling in the ventral hippocampus and its contribution to the acute anxiolytic and social effects of alcohol, as well as the development of alcohol use disorder, in male and female mice. Specifically, the research will examine how...
This $223,531 federal Project Grant awarded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a Phase Ia/b proof-of-concept study to evaluate the potential of the FDA-approved drug diclofenac as a novel treatment for alcohol use disorder (AUD). The primary aim is to identify the optimal dose of diclofenac that can modulate the kynurenine pathway, a key metabolic pathway implicated in AUD, by increasing levels of the...
This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) grant program, provides $211,247 to conduct a Phase II randomized trial of the drug tirzepatide (brand name Zepbound) in adults with co-occurring alcohol use disorder and overweight/obesity. The aim is to evaluate the efficacy of this dual GLP-1/GIP receptor agonist in reducing alcohol consumption and improving weight and cardiometabolic outcomes...
This federal Project Grant award of $223,531, made by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) program, supports the development of novel 3D human brain circuit models to investigate the role of microglia in the neuronal pathology associated with alcohol use disorder (AUD) and Alzheimer's disease (AD). The project aims to employ 3D reciprocal brain circuits composed of human iPSC-derived neurons and microglia to: 1)...
This $145,642 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) will support research to examine patterns of alcohol and cannabis co-use among adolescents, and how these patterns are associated with socioeconomic status and state-level cannabis legalization policies. The research will be conducted by the University of Rhode Island, which will collaborate with researchers from the University of Rhode Island and Rutgers...